Should investors buy Smith & Nephew shares today?

Smith & Nephew shares were crushed during the Covid-19 pandemic and remain well below their highs. Is now the time to buy?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Businesswoman calculating finances in an office

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Smith & Nephew (LSE: SN.) shares have taken a big hit over the last few years. Before Covid, shares in the orthopaedics company were trading around the £20 mark. Today however, they can be picked up for around £12.

Is this a great buying opportunity for long-term investors? Let’s take a look.

Why the share price fell

Smith & Nephew has certainly faced its fair share of challenges in recent years. During the Covid pandemic, many elective surgeries were postponed. This had a big impact on the company’s sales.

The firm has also faced supply chain issues. In recent years, hip and knee implants have become unexpected casualties of raw material shortages.

On top of this, Smith & Nephew has had to deal with inflationary pressures. Margins have been hit by higher commodity and wage costs.

Finally, growth has been also impacted by currency issues, as the company reports in US dollars.

Overall, the operating environment has been very challenging.

Improving outlook

It now looks like Smith & Nephew is starting to turn the corner however.

In a recent trading update, the healthcare company advised that for 2023, it expects revenue growth of 5-6%, above the level of 4.7% reported for 2022.

It also said it expects its medium-term trading profit margin to expand to at least 20% in 2025, versus 17.3% in 2022, on the back of productivity improvements.

We expect to deliver both faster revenue growth and margin expansion in the coming year, and are setting a solid foundation for our mid-term ambitions as we transform to a consistently higher growth company.

Smith & Nephew CEO Deepak Nath

This is all very encouraging.

Looking further out, the prospects for the company remain attractive, to my mind.

This is a business that is well-placed to benefit from the world’s ageing population. Higher numbers of over 65s globally should drive demand for orthopaedic products.

According to Precedence Research, the market for knee implants is expected to grow by around 6% a year between now and 2030.


As for the stock’s valuation, it’s relatively attractive right now, to my mind.

Currently, analysts expect Smith & Nephew to generate earnings per share of 85.3 cents for 2023. That puts the stock on a forward-looking price-to-earnings (P/E) ratio of around 17.

Now that multiple is higher than the FTSE 100 average. However, it’s significantly lower than that of US-listed rival Stryker, which currently has a P/E ratio of about 26.

At the current valuation, I think there’s potential for multiple appreciation if the company can demonstrate that business performance is improving and its transformation plan is working.

Attractive risk/reward

Of course, there are risks here. In the company’s recent results, it noted that it will continue to face macroeconomic headwinds in 2023.

It’s worth pointing out that Smith & Nephew did not recently increase its dividend for 2022. This suggests that management is a little cautious about the future.

Overall however, I like the risk/reward proposition right now. At the current share price, I see the stock as a buy.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon has positions in Smith & Nephew Plc. The Motley Fool UK has recommended Smith & Nephew Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Should I buy more Rolls-Royce shares near 500p?

This investor is wondering whether to buy more Rolls-Royce shares this summer or to just stick with those he already…

Read more »

Investing Articles

After its big fall, is the National Grid share price dirt cheap now?

The National Grid share price fell sharply in reponse to new rights issue plans. But is it an even better…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Starting in June, I’d invest £1,000 a month to aim for a £102,000 second income in retirement

This author highlights a less well-known FTSE 100 stock that could help his portfolio generate a very big second income…

Read more »

Investing Articles

Down 47% in 5 years, is the IAG share price due a bounce?

Many companies in the travel sector have seen fierce rallies since 2020. But with the IAG share price still down…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

Despite its drop, I reckon this is one of the best FTSE 100 stocks to buy and hold!

The FTSE 100 has been climbing in 2024 but this favourite of our writer's has been falling. Despite this, she’s…

Read more »

Investing Articles

AI stocks vs EV shares; which is the best sector for me to invest in?

Jon Smith considers the recent rally in AI stocks and weighs up whether to allocate more money there versus EV…

Read more »

A graph made of neon tubes in a room
Investing Articles

Do Greggs shares have even more growth ahead?

Greggs shares have seen some solid growth in the last few months, as the economy shows positive signs. But is…

Read more »

Investing For Beginners

How I’d aim to grow my Stocks & Shares ISA from £20k to £1m

Jon Smith explains how diversification and focusing on sectors for the future can help grow his Stocks and Shares ISA.

Read more »